Tarsus Pharmaceuticals (NASDAQ:TARS) General Counsel Sells $283,428.75 in Stock

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) General Counsel Bryan Wahl sold 4,125 shares of the firm’s stock in a transaction on Wednesday, March 18th. The stock was sold at an average price of $68.71, for a total value of $283,428.75. Following the completion of the sale, the general counsel directly owned 68,190 shares of the company’s stock, valued at $4,685,334.90. This represents a 5.70% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Bryan Wahl also recently made the following trade(s):

• On Thursday, March 19th, Bryan Wahl sold 4,231 shares of Tarsus Pharmaceuticals stock. The shares were sold at an average price of $67.00, for a total value of $283,477.00.
• On Tuesday, March 17th, Bryan Wahl sold 4,084 shares of Tarsus Pharmaceuticals stock. The shares were sold at an average price of $69.42, for a total value of $283,511.28.

Tarsus Pharmaceuticals Stock Down 3.4%

TARS stock opened at $64.51 on Friday. The stock has a fifty day moving average of $69.12 and a 200-day moving average of $70.30. Tarsus Pharmaceuticals, Inc. has a fifty-two week low of $38.51 and a fifty-two week high of $85.25. The company has a market capitalization of $2.75 billion, a price-to-earnings ratio of -39.82 and a beta of 0.55. The company has a debt-to-equity ratio of 0.21, a quick ratio of 3.82 and a current ratio of 3.85.

Tarsus Pharmaceuticals (NASDAQ:TARS) last announced its quarterly earnings data on Monday, February 23rd. The company reported ($0.20) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.01). The firm had revenue of $151.67 million during the quarter, compared to the consensus estimate of $144.56 million. Tarsus Pharmaceuticals had a negative net margin of 14.72% and a negative return on equity of 19.63%. As a group, equities research analysts predict that Tarsus Pharmaceuticals, Inc. will post -3.17 earnings per share for the current year.

Institutional Investors Weigh In On Tarsus Pharmaceuticals

A number of institutional investors and hedge funds have recently modified their holdings of TARS. Rockefeller Capital Management L.P. grew its position in Tarsus Pharmaceuticals by 15.5% during the fourth quarter. Rockefeller Capital Management L.P. now owns 1,283 shares of the company’s stock worth $105,000 after buying an additional 172 shares in the last quarter. Seven Fleet Capital Management LP purchased a new stake in shares of Tarsus Pharmaceuticals in the 4th quarter valued at about $368,000. Invesco Ltd. raised its holdings in shares of Tarsus Pharmaceuticals by 8.0% in the 4th quarter. Invesco Ltd. now owns 1,012,357 shares of the company’s stock valued at $82,892,000 after acquiring an additional 75,351 shares in the last quarter. Mackenzie Financial Corp bought a new stake in shares of Tarsus Pharmaceuticals during the 4th quarter valued at about $202,000. Finally, XTX Topco Ltd boosted its position in shares of Tarsus Pharmaceuticals by 270.3% during the 4th quarter. XTX Topco Ltd now owns 18,410 shares of the company’s stock valued at $1,507,000 after acquiring an additional 13,438 shares during the last quarter. 90.01% of the stock is owned by hedge funds and other institutional investors.

Key Tarsus Pharmaceuticals News

Here are the key news stories impacting Tarsus Pharmaceuticals this week:

• Positive Sentiment: Lifesci Capital upgraded TARS to “Strong‑Buy” and published narrower FY‑2026 and quarterly EPS losses (they now model materially smaller losses vs. consensus), supporting a more constructive recovery thesis for the name. Lifesci Capital report
• Neutral Sentiment: Street consensus remains mixed-to-favorable (average “Moderate Buy”); Lifesci’s bullish view improves outlook but is not yet unanimous across analysts. Analyst consensus
• Neutral Sentiment: Last reported quarter: slight EPS miss (reported ($0.20) vs. ($0.19) est.) but revenue beat — fundamentals are mixed and future price action depends on clinical/launch catalysts and execution. Quarterly results
• Neutral Sentiment: High institutional ownership (~90%) concentrates the float — can stabilize but also amplify moves if large holders or insiders trade. Ownership details
• Negative Sentiment: Clustered insider selling across Mar 16–19: CEO Bobak Azamian sold multiple tranches (totaling ~34,600 shares across Mar 17–19 at ~$67–$69), Director William J. Link sold 12,500 shares, and several other senior officers trimmed positions — large, concentrated insider sales often create short‑term downward pressure and raise questions about timing/intent. Insider sales roundup
• Negative Sentiment: Multiple SEC Form 4s disclose the CEO’s and other officers’ sales (detailed fills and dates are available in the filings), which investors may view as meaningful liquidity events rather than routine small trades. SEC Form 4 (example)

Analyst Upgrades and Downgrades

A number of analysts recently commented on the stock. Lifesci Capital upgraded shares of Tarsus Pharmaceuticals to a “strong-buy” rating in a research note on Monday, March 16th. Oppenheimer lifted their price objective on shares of Tarsus Pharmaceuticals from $95.00 to $105.00 and gave the company an “outperform” rating in a research note on Wednesday, February 25th. Guggenheim boosted their target price on shares of Tarsus Pharmaceuticals from $87.00 to $90.00 and gave the company a “buy” rating in a report on Wednesday, February 25th. Zacks Research downgraded Tarsus Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, February 25th. Finally, Barclays assumed coverage on Tarsus Pharmaceuticals in a report on Monday, December 8th. They issued an “overweight” rating and a $100.00 price target for the company. Two equities research analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $91.83.

About Tarsus Pharmaceuticals

Tarsus Pharmaceuticals, Inc is a clinical‐stage biopharmaceutical company focused on developing novel therapies for diseases of the eye and ocular surface. The company’s research platform centers on neuro‐effector modulation to address underlying disease mechanisms rather than solely treating symptoms. Tarsus’s lead candidate, OC-01 (varenicline solution), is an intranasal formulation in Phase 3 development for the treatment of dry eye disease, a condition affecting millions worldwide and associated with significant patient discomfort and reduced quality of life.

In addition to its dry eye program, Tarsus is advancing preclinical and early‐stage programs targeting other ophthalmic indications, including allergic conjunctivitis and retinal disorders.